<DOC>
	<DOCNO>NCT00660153</DOCNO>
	<brief_summary>The FOLFOX6 regimen standard chemotherapy regimen treatment patient colorectal cancer gastrointestinal cancer . Tivozanib ( AV-951 ) target anti-angiogenesis agent demonstrate acceptable tolerability phase I clinical trial . This study design test hypothesis tivozanib ( AV-951 ) combine standard FOLFOX6 chemotherapy treatment patient colorectal gastrointestinal cancer . The purpose study determine maximum dose tivozanib ( AV-951 ) safely combine FOLFOX6 chemotherapy , evaluate safety profile , tolerability , pharmacokinetics combination .</brief_summary>
	<brief_title>Study Tivozanib ( AV-951 ) Plus FOLFOX6 Subjects With Advanced Colorectal Cancer Other Gastrointestinal Cancers</brief_title>
	<detailed_description>This Phase 1b , open-label , study design examine safety , tolerability , maximum tolerate dose tivozanib ( AV-951 ) FOLFOX6 advance colorectal cancer gastrointestinal cancer . In study , dose tivozanib ( AV-951 ) escalate 0.5 mg/day 1.5 mg/day . All subject receive standard dos FOLFOX6 chemotherapy every 2 week .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<criteria>1 . ≥ 18yearold male females 2 . Histologically cytologically confirm metastatic colorectal cancer gastrointestinal malignancy FOLFOX6 chemotherapy standard treatment . Other gastrointestinal cancer include , limited , esophageal , gastric , small intestine , appendiceal , pancreaticobiliary cancer . 3 . Documented progressive disease 4 . Measurable evaluable disease RECIST . ( Note : Subjects enrol MTD Expansion Cohort require measurable disease , accord RECIST . ) 5 . No 2 prior chemotherapy regimens metastatic disease ( This include prior adjuvant chemotherapy fluorouracil and/or oxaliplatin . ) 6 . At least 3 week since prior treatment : Chemotherapy ( least 6 week nitrosoureas , mitomycin C , liposomal doxorubicin ) Agents target VEGF pathway ( eg , bevacizumab , sunitinib , sorafenib , etc . ) Other signal transduction inhibitor monoclonal antibody Immunotherapy biological response modifier Systemic hormonal anticancer therapy , exception LHRH agonists prostate cancer Any experimental therapy 7 . Resolution toxicity associate prior chemotherapy ≤ Grade 1 ( except Grade 2 alopecia ) 8 . ECOG performance status ≤ 2 ( see Appendix A ) life expectancy ≥ 3 month 9 . No childbearing potential use effective contraception fertile male female subject study 30 day last dose study drug . All subject must agree use highly effective method contraception ( include partner ) . Effective birth control include ( ) IUD plus one barrier method ; ( b ) 2 barrier method . Effective barrier method male female condom , diaphragm , spermicide ( creams gel contain chemical kill sperm ) . Oral , implantable , injectable contraceptive may affect cytochrome P450 interaction , therefore consider effective study . 10 . Dated sign informed consent 1 . Primary CNS malignancy clinically active CNS metastases 2 . Hematologic malignancy ( include leukemia form , lymphoma , multiple myeloma ) 3 . Any following hematologic abnormality : Hemoglobin &lt; 9.0 g/dL ANC &lt; 1500 per mm3 Platelet count &lt; 100,000 per mm3 4 . Any following serum chemistry abnormality : Total bilirubin &gt; 1.5 × ULN AST ALT &gt; 2.5 × ULN ( &gt; 5 x ULN subject liver metastasis ) GGT &gt; 2.5 x ULN ( &gt; 5 x ULN subject liver metastasis ) Alkaline Phosphatase &gt; 2.5 x ULN ( &gt; 5 x ULN subject liver bone metastasis ) Serum albumin &lt; 3.0 g/dL Creatinine &gt; 1.5 × ULN ( calculate CLCR &lt; 50 mL/min/1.73 m2 ) Proteinuria &gt; 2.5 g/24 hour 3+ urine dipstick Any ≥ Grade 3 laboratory abnormality baseline ( list ) 5 . Significant cardiovascular disease , include : Active clinically symptomatic leave ventricular failure Active HTN ( diastolic blood pressure &gt; 100 mmHg ) . Subjects history hypertension must stable dos antihypertensive drug ≥ 4 week prior start Cycle 1 Uncontrolled hypertension : Blood pressure &gt; 140/90 mmHg 2 antihypertensive medication Myocardial infarction within 3 month prior start Cycle 1 6 . Serious/active infection , infection require parenteral antibiotic 7 . Inadequate recovery prior surgical procedure major surgical procedure within 6 week prior start Cycle 1 8 . Unhealed wound , ulcer , bone fracture 9 . Ongoing hemoptysis history clinically significant bleed 10 . Cerebrovascular accident within 12 month prior start Cycle 1 , peripheral vascular disease claudication walk less 1 block 11 . Deep venous thrombosis pulmonary embolus within 12 month prior start Cycle 1 and/or ongoing need fulldose oral parenteral anticoagulation 12 . History ≥ Grade 3 hypersensitivity reaction prior exposure oxaliplatin 13 . Subjects `` currently active '' second malignancy nonmelanoma skin cancer localize prostate cancer ( stable PSA least 3 month prior start Cycle 1 ) . Subjects consider `` currently active '' malignancy complete anticancer therapy consider physician &lt; 30 % risk relapse . 14 . Lifethreatening illness organ system dysfunction compromise safety evaluation 15 . Uncontrolled psychiatric disorder alter mental status precluding inform consent necessary test 16 . Inability comply protocol requirement 17 . Pregnant lactate woman 18 . Known concomitant genetic acquire immune suppression disease , HIV 19 . Consumption herbal preparations/supplements ( except daily multivitamin/mineral supplement contain herbal component ) within 2 week prior start Cycle 1 20 . Prior radiotherapy : Local radiation therapy ( involve ≤ 25 % bone marrow ) within 2 week prior start Cycle 1 Craniospinal radiotherapy within 3 month prior start Cycle 1 Radiotherapy : whole abdomen pelvis , whole lung , &gt; 25 % bone marrow , total body irradiation within 6 month prior start Cycle 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Advanced Colorectal Cancer Other Gastrointestinal Cancers</keyword>
	<keyword>tivozanib</keyword>
	<keyword>AV-951</keyword>
</DOC>